Compound class:
Synthetic organic
Comment: JBJ-04-125-02 is a fourth generation EGFR inhibitor [1]. It has an allosteric mode of action, and acts synergistically with the ATP-competitive inhibitor osimertinib.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Bioactivity Comments |
JBJ-04-125-02 inhibits EGFRL858R/T790M/C797S signalling, and cell proliferation in vitro and in vivo [1]. It is unable to bind Del_19-containing EGFR mutants, and does not inhibit proliferation of parental Ba/F3, wild-type EGFR Ba/F3 cells or Ba/F3 cells expressing any of the EGFRDel_19 variants. |
Selectivity at catalytic receptors | ||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|